Dyne Therapeutics started the new year with proof-of-concept clinical data for experimental genetic medicines addressing two rare muscle diseases—one of which has no FDA-approved treatments. Now the ...
Dyne pursues rare disease breakthroughs while Vertex leverages blockbuster profits for pipeline expansion, how do their risk ...
- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 mg/kg Cohort at 3 Months - - DYNE-101 Showed Improvement in Myotonia, ...
TROY, NY, UNITED STATES, February 5, 2026 /EINPresswire.com/ — Inspect Point, the leading SaaS platform for fire and life safety inspection, testing, and compliance ...
The phase 3 study “A Phase 3, Randomized, Double-Blind, 48-Week Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of DYNE-101 Administered to Participants With Myotonic ...
Inspect Point has partnered with Dyne Fire Protection Labs to connect sprinkler sampling and lab testing with inspection workflows. TROY, NY, UNITED STATES, February ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results